Diacurimap Quiz 17-12-2023 PDF

**[DIACURIMAP Quiz ]** **[17-12-2023]** **NAME:...................................** **[A-Choose TRUE Or FALSE in The following Questions: ]** 1-Empagliflozin in HF patients can be administered up to GFR 30 ( false ) 20 2-Sulfonylurea is neutral on body weight ( false ) increase 3-The only SGL...

**[DIACURIMAP Quiz ]** **[17-12-2023]** **NAME:...................................** **[A-Choose TRUE Or FALSE in The following Questions: ]** 1-Empagliflozin in HF patients can be administered up to GFR 30 ( false ) 20 2-Sulfonylurea is neutral on body weight ( false ) increase 3-The only SGLT2i reduce cardio vascular death is Empagliflozin ( True ) 4-one of the SE of insulin is increased risk of hypoglycemia ( True ) 5-HFpEF is Greater than or = 50 ( True ) 6- In Emperor Reduced study , the risk of Composite renal outcome reduced 27 % ( false ) 50 7-In Emperor Preserved study , risk of total ( first and recurrent ) HF Hospitalization Reduced by 27 % ( true ) 8-UKPDS Reveals that at time of diagnosis 70 % of beta cells function already lost ( False ) 9-Reduction of all cause mortality in EMPA REG trial was 30 % ( false) 32 10-approved dose of dapagliflozin is 5mg ( false ) 10 mg 11-Empakidny trial Hospitalization by any cause by 16 % ( False ) 14% 12-3P MACE is first occurrence of all cause mortality ,non fatal MI ,non fatal stroke( fasle ) CV Death 13-Diacurimap has 9% fold less hypoglycemia than SU ( false ) 10 % 14-Empaliflozin is recommended in ESC 2021 HF Guidelines class 1A recommendation ( true ) 15-EF (ejection fraction ) is a measurement of % of blood Leaving the heart Each time it contracts ( true) 16-in empakidney trial the risk of kidney disease progression or cv death reduced by 29 % (false) 28 % 17-in comparison between empagliflozin and glimipride the body weight difference between them was 2.7 kg (false) 4.7 18-reduction of doubling serum creatinine with empagliflozin in EmpaReg trial was 45 % (false ) 44% 19-the approved dose of empagliflozin in HF is 5mg (false) 10 20-EMPAREG study enrolls 3730 While Emperor Reduced 7020 Patient ( false) inverted **[B- Complete the following :]** 1. MACE Stands For \_major adverse cardio vascular events 2. NNT Stands For \_number needed to treat 3. MOA Stands For \_ Mechanism of action 4. (HR) in EMPAREG study or any other study stands for \_ hazard ratio 5. RRR Stands for \_ relative risk reduction 6. An example of bigunaides \_ metformin and for DPP-4 I \_ vildagliptin and for Sulfonylurea\_glimipride And for GlP 1\_\_\_semaglutide And for A-Glucosidase inhibitors \_miglitol 7. Contraindications of Empagliflozin \_ lactation \-\-- pregnancy -- type 1---hypersensetivity- not above 18 -- renal \< 45 8. CV outcomes of EmpaREG trial are 14 % 3p mace - 32 all cause -- 38 cv death 35 HHF 9. Renal Outcomes Of EmpaREG Trial are \_ 39 nephro 38 macro 44 doub serum 55 renal R 4-\_\_\_\_ kg in body weight can significally improve glycemic control and reduce morbidity Mortality (-1) -6 -4 -8 5- \_\_\_ Reduction in new onset or worsening Nephropathy -60 (-39) -55 -38 6- beating the other SGLT2 by ensuring more patient adherence by saving \_\_%vs dapa -70 -50 (-60 ) -30 7-in empakidney , empagliflozin RRR of CKD and cv death and hospitalization by -23&10 -3& 14 ( -28&14 ) -80&30 8- Empacoza is of \_\_\_\_\_ company -Eva -Habib (- Zeta) - Sanofi 9-melitofix is of \_\_\_\_\_\_ company (-Eva) -Habib - Zeta - Sanofi 10-Diacurimap provide Marked delay in insulin initiation by % -50 (-60) -80 -44 **[D-Match the graphs with title:]**